Chris De Savi: Breaking News from WCLC24

Chris De Savi shared a post on LinkedIn:

”Ivonescimab Outshines Keytruda in 1st Line Lung Cancer: A Game-Changer in Oncology?

Breaking News from WCLC24!

The 2024 World Conference on Lung Cancer unveiled a groundbreaking advancement in treating non-small cell lung cancer (NSCLC). Ivonescimab has set a new benchmark, outpacing Keytruda (pembrolizumab) in the first-line treatment of lung cancer! This fresh data from the latest Phase 3 trial is nothing short of WOW.

For the first time, a novel drug has shown a clinically significant improvement in efficacy compared to the established pembrolizumab in NSCLC with positive PD-L1 (TPS ≥1%).

Key Highlights:

Ivonescimab’s Impressive Performance:

• Progression-Free Survival (PFS): Ivonescimab significantly outperforms pembrolizumab, with a median PFS of 11.14 months versus 5.82 months. The hazard ratio is an impressive 0.51 (p<0.0001), marking a significant leap forward in treatment efficacy.
• Consistency Across Subgroups: Whether TPS ≥50% or TPS 1-49%, ivonescimab shows robust benefits. The results are consistent across squamous (SQ) and non-squamous (non-SQ) subtypes.
• Higher Response Rates: Ivonescimab delivers a higher overall response rate (ORR) of 50.0% compared to 38.5% with pembrolizumab and a dramatically improved disease control rate (DCR) of 89.9% versus 70.5%.

What’s Next?

While overall survival (OS) data is still maturing, this event-driven analysis will be eagerly awaited. Ivonescimab’s safety profile aligns with previous studies and is well-tolerated, even in patients with SQ-NSCLC.

Quality of Life (HRQoL) with ivonescimab is on par with pembrolizumab, maintaining patient well-being without compromising efficacy.

What makes Ivonescimab so unique?

Ivonescimab is a cutting-edge PD-1/VEGF bispecific antibody that combines two powerful mechanisms into one tetravalent molecule. By targeting both vascular endothelial growth factor (VEGF) and PD-1, it blocks the PD-1 pathway and enhances the immune system’s ability to target and destroy tumor cells. This dual-action approach could reshape the immune environment, making it more hostile to tumors and more responsive to treatment.

We await OS data….until then, enjoy the rest of the weekend.

Follow Chris De Savi or ring the icon to be notified of all his posts.”

Read further.
Source: Chris De Savi/LinkedIn

Chris De Savi is the Chief Scientific Officer and Partner at Curie.Bio, where he leverages his drug discovery expertise and seed investment experience to help founders launch therapeutics companies that successfully secure subsequent financing. He is also the founder of the Drug Hunting Literature Group.